Contact Information

Available for logged-in reporters only

Newswise LA JOLLA-The ability to switch out one gene for another in a line of living stem cells has only crossed from science fiction to reality within this decade. As with any new technology, it brings with it both promise--the hope of fixing disease-causing genes in humans, for example--as well as questions and safety concerns. Now, Salk scientists have put one of those concerns to rest: using gene-editing techniques on stem cells doesn't increase the overall occurrence of mutations in the cells. The new results were published July 3 in the journal Cell Stem Cell.

"The ability to precisely modify the DNA of stem cells has greatly accelerated research on human diseases and cell therapy," says senior author Juan Carlos Izpisua Belmonte, professor in Salk's Gene Expression Laboratory. "To successfully translate this technology into the clinic, we first need to scrutinize the safety of these modified stem cells, such as their genome stability and mutational load."

When scientists want to change the sequence of a stretch of DNA inside cells--either for research purposes or to fix a genetic mutation for therapeutic purposes--they have their choice of two methods. They can use an engineered virus to deliver the new gene to a cell; the cell then integrates the new DNA sequence in place of the old one. Or scientists can use what's known as custom targeted nucleases, such as TALEN proteins, which cut DNA at any desired location. Researchers can use the proteins to cut a gene they want to replace, then add a new gene to the mix. The cell's natural repair mechanisms will paste the new gene in place.

Previously, Belmonte's lab had pioneered the use of modified viruses, called helper-dependent adenoviral vectors (HDAdVs) to correct the gene mutation that causes sickle cell disease, one of the most severe blood diseases in the world. He and his collaborators used HDAdVs to replace the mutated gene in a line of stem cells with a mutant-free version, creating stem cells that could theoretically be infused into patients' bone marrow so that their bodies create healthy blood cells.

Before such technologies are applied to humans, though, researchers like Belmonte wanted to know whether there were risks of editing the genes in stem cells. Even though both common gene-editing techniques have been shown to be accurate at altering the right stretch of DNA, scientists worried that the process could make the cells more unstable and prone to mutations in unrelated genes--such as those that could cause cancer.

"As cells are being reprogrammed into stem cells, they tend to accumulate many mutations," says Mo Li, a postdoctoral fellow in Belmonte's lab and an author of the new paper. "So people naturally worry that any process you perform with these cells in vitro--including gene editing--might generate even more mutations."

To find out whether this was the case, Belmonte's group, in collaboration with BGI and the Institute of Biophysics, Chinese Academy of Sciences in China, turned to a line of stem cells containing the mutated gene that causes sickle cell disease. They edited the genes of some cells using one of two HDAdV designs, edited others using one of two TALEN proteins, and kept the rest of the cells in culture without editing them. Then, they fully sequenced the entire genome of each cell from the four edits and control experiment.

While all of the cells gained a low level of random gene mutations during the experiments, the cells that had undergone gene-editing--whether through HDAdV- or TALEN-based approaches--had no more mutations than the cells kept in culture.

View post:
No Extra Mutations in Modified Stem Cells, Study Finds

The ability to switch out one gene for another in a line of living stem cells has only crossed from science fiction to reality within this decade. As with any new technology, it brings with it both promise-the hope of fixing disease-causing genes in humans, for example-as well as questions and safety concerns.

Now, Salk scientists have put one of those concerns to rest: using gene-editing techniques on stem cells doesn't increase the overall occurrence of mutations in the cells. The new results were published July 3 in the journal Cell Stem Cell.

"The ability to precisely modify the DNA of stem cells has greatly accelerated research on human diseases and cell therapy," says senior author Juan Carlos Izpisua Belmonte, professor in Salk's Gene Expression Laboratory. "To successfully translate this technology into the clinic, we first need to scrutinize the safety of these modified stem cells, such as their genome stability and mutational load."

When scientists want to change the sequence of a stretch of DNA inside cells-either for research purposes or to fix a genetic mutation for therapeutic purposes-they have their choice of two methods. They can use an engineered virus to deliver the new gene to a cell; the cell then integrates the new DNA sequence in place of the old one.

Or scientists can use what's known as custom targeted nucleases, such as TALEN proteins, which cut DNA at any desired location. Researchers can use the proteins to cut a gene they want to replace, then add a new gene to the mix. The cell's natural repair mechanisms will paste the new gene in place.

Previously, Belmonte's lab had pioneered the use of modified viruses, called helper-dependent adenoviral vectors (HDAdVs) to correct the gene mutation that causes sickle cell disease, one of the most severe blood diseases in the world.

He and his collaborators used HDAdVs to replace the mutated gene in a line of stem cells with a mutant-free version, creating stem cells that could theoretically be infused into patients' bone marrow so that their bodies create healthy blood cells.

Before such technologies are applied to humans, though, researchers like Belmonte wanted to know whether there were risks of editing the genes in stem cells. Even though both common gene-editing techniques have been shown to be accurate at altering the right stretch of DNA, scientists worried that the process could make the cells more unstable and prone to mutations in unrelated genes-such as those that could cause cancer.

"As cells are being reprogrammed into stem cells, they tend to accumulate many mutations," says Mo Li, a postdoctoral fellow in Belmonte's lab and an author of the new paper. "So people naturally worry that any process you perform with these cells in vitro-including gene editing-might generate even more mutations."

To find out whether this was the case, Belmonte's group, in collaboration with BGI and the Institute of Biophysics, Chinese Academy of Sciences in China, turned to a line of stem cells containing the mutated gene that causes sickle cell disease.

See the original post here:
No extra mutations in modified stem cells

Histogen's chief executive, Gail Naughton.

Histogen, a San Diego biotech company developing a hair loss treatment from stem cells, has established a joint venture for cancer therapy.

Privately held Histogen has created the venture, Histogen Oncology, in partnership with the medical device company Wylde LLC. Wylde contributed $2.5 million, said Gail Naughton, the company's chief executive.

The company's technology grows young skin cells called fibroblasts under simulated embryonic conditions, including low oxygen levels. The company says these conditions cause the cells to become embryonic-like, making proteins and substances called growth factors characteristic of young tissue. Histogen uses these substances in its various products.

Histogen Oncology uses certain of these substances that enable cancer cells to undergo programmed cell death, or apoptosis. These substances turn on a gene that controls apoptosis, which naturally occurs in damaged cells, Naughton said.

Since the cancer cells are genetically abnormal, they begin to self-destruct when apoptosis is triggered. Normal cells are not affected, because the apoptosis mechanism is already turned on, she said. The loss of this mechanism is a hallmark of cancer.

Histogen Oncology intends intends to apply within 18 months to start clinical trials in Stage 4 advanced metastatic pancreatic cancer, Naughton said. This cancer is a good target because it has a high mortality rate, so better therapies are urgently needed, she said.

There's an average 6.7 percent survival rate for patients over a five-year period after diagnosis with pancreatic cancer, according to the National Cancer Institute.

"We're hoping that we're going to see an increase in the person's life, without any toxic side effects," Naughton said.

The substances will be given either intravenously or injected into the abdominal cavity.

Read this article:
Histogen forms cancer joint venture

Council of Scientific and Industrial Research (CSIR) Centre for Cellular and Molecular Biology (CCMB) Director, Dr Ch. Mohan Rao today claimed that the heart disease can be treated without surgeries in future.

Addressing after inaugurating the 19th Annual conference of the Cardiological Society of India (CSI-AP Chapter) here, Dr Rao said that in the recent research in molecular biology found that 'heart' too have 'stem cells' which will help to automatically build the damaged part of any organ.

He said that further research also going with collaboration of other foreign institutions on how to bring the 'stem cells' out and repair.

Once the solution is found, the cardiac diseases can be healed with surgery, Dr Rao said.

''This development will make the stem cell based therapy replace the chemical based therapy in Cardiology,'' he added.

Irregular eating habits and busy lifestyle are among the major causes of the cordial illness, he said and advised to the youth to follow healthy lifestyle to avoid heart related problems.

While talking about the latest research, he said, ''To reduce the deaths due to cardiac illness the CCMB is working along with the scientists from Japan, the US and Italy to develop the an easier way to treatment.''

Dr Rao also given a clarion call to Cardiology experts to come forward for joint research on cardiac problems.

Encouraging the research in Cardiology, Dr Rao also invited the young medicos to visit the CCMB campus and work with the institute.

Discussing various kinds of heart diseases, he said, ''Dilated Cardiomyopathy is one of the most common heart disease among the children.''

Continue reading here:
Cardiac diseases to be treated without surgeries soon as stem cells found

It sounds like something straight out of science fiction: stem cells from donated placentas are being injected into patients with hard-to-heal injuries. The results have been phenomenal, all by taking advantage of something that would be discarded as medical waste.

The stem cells inside a tiny vial will morph into something totally new once injected into the body. Dr. Brett Cascio is the Medical Director of Sports Medicine at Lake Charles Memorial Hospital and he is using this cutting edge technology in some of his toughest cases. We've know the special nature of stem cells for years, decades, he said, but harvesting them and getting them to do what we want them to do is the difficult part.

Dr. Cascio has treated all sorts of injuries - some that just have a tough time healing. For some reason along the way, their healing either stopped or went haywire and they didn't heal correctly, he said, and they need help on the cellular level to heal their problem.

That is where stem cells come in: not from a live human being, but from a donated placenta. The cells are tested, prepared and frozen until needed. One placenta can help hundreds of patients. You don't reject these cells, said Dr. Cascio, your body recognizes them as a potential healing factor and helps it to heal itself.

That healing is something Chad Theriot was desperate to find after rupturing the longest ligament in his foot while playing basketball. I heard a loud pop, he said, and then instant pain. I knew immediately that something was wrong.

Months passed with Theriot on crutches, in a boot, in pain and unable to be the family man he wanted to be. My wife was having to pick up slack everywhere, he said, at home, at work, with the baby.. I wasn't able to help much.

A second opinion brought Theriot to Dr. Cascio. The plan was to inject stem cells into the bottom of Theriot's foot , having them grow into good, healthy tissue in the place of what was damaged. So if you put them in connective tissue or skin, they can grow into skin-type cells or in muscle, they can grow into muscle-type cells, said Dr. Cascio.

Patients are given twilight anesthesia and the injections are given under X-ray guidance. The actual injection only takes one minute. Two weeks later I was taking unassisted steps and my pain level on a scale from one to ten went from an eight to a two, said Theriot.

That was the first time Theriot walked without help in four months. That was a big day for me, he said, that was a big day for us.

This stem cell technology is still in its early stages, but Dr. Cascio says the future is exciting. These are not magical cells, it's not like pixie dust, but they help the body heal itself and you can get some really amazing results, he said.

Read the rest here:
Stem cells from donated placentas healing stubborn injuries

By Steven Reinberg HealthDay Reporter

TUESDAY, July 1, 2014 (HealthDay News) -- A new bone marrow transplant technique for adults with sickle cell disease may "cure" many patients. And it avoids the toxic effects associated with long-term use of anti-rejection drugs, a new study suggests.

This experimental technique mixes stem cells from a sibling with the patient's own cells. Of 30 patients treated this way, many stopped using anti-rejection drugs within a year, and avoided serious side effects of transplants -- rejection and graft-versus-host disease, in which donor cells attack the recipient cells, the researchers said.

"We can successfully reverse sickle cell disease with a partial bone marrow transplant in very sick adult patients without the need for long-term medications," said researcher Dr. John Tisdale, a senior investigator at the U.S. National Heart, Lung, and Blood Institute.

In the United States, more than 90,000 people have sickle cell disease, a painful genetic disorder found mainly among blacks. Worldwide, millions of people have the disease.

Many adults with sickle cell disease have organ damage. This makes them ineligible for traditional transplants, which destroy all their bone marrow cells and use unmatched donor cells, he said. "Doing it this way would allow them access to a potential cure," Tisdale said.

"Adult patients, in whom symptoms are very severe, should consider whether a transplant could be right for them," he said. "A simple blood test for their siblings could tell them whether this approach is an option."

One expert was enthusiastic about the report, published July 2 in the Journal of the American Medical Association.

"The outcomes look every bit as good, if not better, than anything reported so far," said Dr. John DiPersio, chief of the division of oncology at Washington University School of Medicine in St. Louis.

"The issue is whether this can be extended to unrelated donors and to mismatched donors," said DiPersio, also the author of an accompanying journal editorial.

Continued here:
Less Toxic Transplant Treatment Offers Hope for Sickle Cell Patients

hide captionThe heart beats in a mouse embryo grown with stem cells made from blood. Now the research that claimed a simple acid solution could be used to create those cells has been retracted.

The heart beats in a mouse embryo grown with stem cells made from blood. Now the research that claimed a simple acid solution could be used to create those cells has been retracted.

A prestigious scientific journal Wednesday took the unusual step of retracting some high-profile research that had generated international excitement about stem cell research.

The British scientific journal Nature retracted two papers published in January by scientists at the Riken research institute in Japan and at Harvard Medical School that claimed that they could create stem cells simply by dipping skin and blood cells into acid.

The claim raised the possibility of being able to use the cells to easily make any kind of cell in the body to treat many diseases and generated international media coverage, including some on Shots.

But other scientists almost immediately raised questions about the papers, and investigators eventually found that the research papers contained many errors. In April, Riken even concluded that Haruko Obokata, the main Japanese scientist, was guilty of scientific misconduct.

The scientists involved in the work, including Charles Vacanti at the Harvard-affiliated Brigham and Women's Hospital in Boston, issued statements regretting the problems with the papers and agreeing that they should be retracted.

"I am deeply saddened by all that has transpired, and after thoughtful consideration of the errors presented in the Riken report and other concerns that have been raised, I have agreed to retract the papers," Vacanti wrote in a statement.

But Vacanti and Obokata said they still believed their techniques could work. In fact, Riken recently agreed to allow Obokata to participate in an experiment aimed at attempting to reproduce the original results.

For its part, the journal Nature said it was reviewing its policies to try to prevent future flawed papers from being published and published retractions of the two original papers as well as the editorial that accompanied them.

See more here:
Easy Method For Making Stem Cells Was Too Good To Be True

PUBLIC RELEASE DATE:

2-Jul-2014

Contact: Kristina Grifantini press@salk.edu Salk Institute

LA JOLLA-Researchers around the world have turned to stem cells, which have the potential to develop into any cell type in the body, for potential regenerative and disease therapeutics.

Now, for the first time, researchers at the Salk Institute, with collaborators from Oregon Health & Science University and the University of California, San Diego, have shown that stem cells created using two different methods are far from identical. The finding could lead to improved avenues for developing stem cell therapies as well as a better understanding of the basic biology of stem cells.

The researchers discovered that stem cells created by moving genetic material from a skin cell into an empty egg cell-rather than coaxing adult cells back to their embryonic state by artificially turning on a small number of genes-more closely resemble human embryonic stem cells, which are considered the gold standard in the field.

"These cells created using eggs' cytoplasm have fewer reprogramming issues, fewer alterations in gene expression levels and are closer to real embryonic stem cells," says co-senior author Joseph R. Ecker, professor and director of Salk's Genomic Analysis Laboratory and co-director of the Center of Excellence for Stem Cell Genomics. The results of the study were published today in Nature.

Human embryonic stem cells (hESCs) are directly pulled from unused embryos discarded from in-vitro fertilization, but ethical and logistical quandaries have restricted their access. In the United States, federal funds have limited the use of hESCs so researchers have turned to other methods to create stem cells. Most commonly, scientists create induced pluripotent stem (iPS) cells by starting with adult cells (often from the skin) and adding a mixture of genes that, when expressed, regress the cells to a pluripotent stem-cell state. Researchers can then coax the new stem cells to develop into cells that resemble those in the brain or in the heart, giving scientists a valuable model for studying human disease in the lab.

Over the past year, a team at OHSU built upon a technique called somatic cell nuclear transfer (the same that is used for cloning an organism, such as Dolly the sheep) to transplant the DNA-containing nucleus of a skin cell into an empty human egg, which then naturally matures into a group of stem cells.

Ecker, holder of the Salk International Council Chair in Genetics, teamed up with Shoukhrat Mitalipov, developer of the new technique and director of the Center for Embryonic Cell and Gene Therapy at OHSU, and UCSD assistant professor Louise Laurent to carry out the first direct comparison of the two approaches. The scientists created four lines of nuclear transfer stem cells all using eggs from a single donor, along with seven lines of iPS cells and two lines of the gold standard hESCs. All cell lines were shown to be able to develop into multiple cell types and had nearly identical DNA content contained within them.

See the original post:
Some stem cell methods closer to 'gold standard' than others

PUBLIC RELEASE DATE:

1-Jul-2014

Contact: Krysten Carrera krysten.carrera@nih.gov 301-435-8112 The JAMA Network Journals

Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in the July 2 issue of JAMA.

Myeloablative (use of high-dose chemotherapy or radiation) allogeneic hematopoietic stem cell transplantation (HSCT; receipt of hematopoietic stem cells "bone marrow" from another individual) is curative for children with severe sickle cell disease, but associated toxicity has made the procedure prohibitive for adults. The development of nonmyeloablative conditioning regimens (use of lower doses of chemotherapy or radiation to prepare the bone marrow to receive new cells) may facilitate safer application of allogeneic HSCT to eligible adults, according to background information in the article.

Matthew M. Hsieh, M.D., of the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md., and colleagues explored a nonmyeloablative approach in a pilot group of 10 adults with severe sickle cell disease, using a simplified HSCT regimen (with stem cell donation from a immunologically matched sibling), that had few toxic effects, yet all patients continued taking immunosuppression medication. The researchers have since revised the protocol to include an option to stop immunosuppression after 1 year in selected patients (those with donor CD3 engraftment of greater than 50 percent and normalization of hemoglobin). In this report, the authors describe the outcomes for 20 additional patients with severe sickle cell disease, along with updated results from the first 10 patients. All 30 patients (ages 16-65 years) were enrolled in the study from July 2004 to October 2013.

As of October 25, 2013, 29 patients were alive with a median follow-up of 3.4 years, and 26 patients (87 percent) had long-term stable donor engraftment without acute or chronic graft-vs-host disease. Hemoglobin levels improved after HSCT; at 1 year, 25 patients (83 percent) had full donor-type hemoglobin. Fifteen engrafted patients discontinued immunosuppression medication and had no graft-vs-host disease.

The average annual hospitalization rate was 3.2 the year before HSCT, 0.63 the first year after, 0.19 the second year after, and 0.11 the third year after transplant. Eleven patients were taking narcotics long-term at the time of transplant. During the week they were hospitalized and received their HSCT, the average narcotics use per week was 639 mg of intravenous morphine-equivalent dose. The dosage decreased to 140 mg 6 months after the transplant.

There were 38 serious adverse events including pain, infections, abdominal events, and toxic effects from the medication sirolimus.

"In this article, we extend our previous results and show that this HSCT procedure can be applied to older adults, even those with severe comorbid conditions " the authors write. "These data reinforce the low toxicity of this regimen, especially among patients with significant end-organ dysfunction."

Read the original here:
Bone marrow transplantation shows potential for treating adults with sickle cell disease

UVA joins National Marrow Donor Program giving greater access to cancer treatments by Ishaan Sachdeva | Jun 25 2014 | 06/25/14 10:11pm | Updated 14 hours ago

The Emily Couric Cancer Center of the University of Virginia Health System has expanded its access to bone marrow and hematopoietic stem cell transplant donors. Now designated as a National Marrow Donor Program (NMDP), the Health System will have access to the Be The Match Registry, the worlds largest and most diverse bone marrow registry. Implications of this change are significant for patients afflicted with blood cancers like leukemia who obtain treatment through the Health System.

Bone marrow, the soft, spongy tissue within bones like the sternum or the ilium of the pelvis, forms hematopoietic or blood-forming stem cells. These cells, unlike embryonic stem cells, differentiate only into types of blood cells- red blood cells, white blood cells or clotting platelets. Leukemia causes bone marrow to produce abnormal, leukemic white blood cells that divide uncontrollably, forming tumors that deprive cells of oxygen and reduce infection defense. One treatment method is autologous bone marrow transplant, in which patients receive stem cells from their healthy, non cancerous bone marrow.

The idea [of autologous transplants] is that you extract healthier bone marrow from the patient to have a source of stored, non-cancerous bone marrow. You can then treat the patient with higher doses of treatment than you can normally give because the most common limitation to treatment is that treatment will kill off healthy bone marrow you might have, said Thomas P. Loughran Jr., MD, the Universitys Cancer Center director.

Essentially, a patients healthy bone marrow is safeguarded outside their body while aggressive treatment is administered to kill cancerous marrow. Another form of treatment is allogeneic treatment, in which bone marrow is transplanted from a sibling or an unrelated donor.

In an allogeneic transplant, you are also transplanting in a new immune system. The new immune system comes in and recognizes the body as a foreign tissue and starts attacking that tissue. This causes a beneficial graft vs. leukemia effect where this new immune system attacks any residual leukemia, but may also cause a harmful graft versus host disease where normal tissue is also attacked, Loughran said.

The donor and recipient tissue interaction underscores the genetic component of bone marrow transplants from external donors. Despite the curative potential of a bone marrow transplant, a strong genetic match between donor and recipient is crucial to the utility of a transplant.

The ability of any donor to be successful is based on genetics. Its called HLA [human leukocyte antigen] typing. The HLA system has four genes called A, B, C and D, and it turns out that A, B and D are influential. We have half of our genes each from both parents, so we have six of these: 2 A, 2 B and 2 D. The best case is a six out of six match from a brother or sister, but the chances are only 1 in 4, said Loughran. The consequence of low genetic probabilities is a large pool of unrelated donors, like the Be The Match Registry. Through such services, patients have a greater chance of finding an unrelated donor who may provide a successful genetic match.

The coordinating center would identify the place where the donor is living and tell them they are potentially able to donate. In the past, the donor would have bone marrow directly extracted. Now it is almost always from the PBSCT [peripheral blood stem cell transplantation] procedure. The donor takes a growth factor that stimulates growth of the needed hematopoietic stem cells within their peripheral blood circulation. A catheter collects this blood and the stem cells are separated from the blood by a machine, and the blood is returned back to the donor. The collected stem cells are sent to the lab where they are purified and frozen, Loughran said.

Meanwhile, the patient in preparation for the transplant is given the highest dose of chemotherapy that can be tolerated. The donated stem cells are administered to the patient in a way similar to IV fluid.

See the rest here:
UVA Expands Cancer Treatment

In the second part of our series on the need for bone marrow donors, NY1's Erin Billups takes a look at what goes into donating bone marrow and some of the lingering misconceptions.

Following the death of their colleague, Marlon Layne, members of the marketing firm Ogilvy & Mather started a campaign to get the word out about the prevalence of blood cancers and the need for more diversity within the donor pool.

Over the past three years they've raised nearly $42,000 for the cause and signed up around 160 new donors to the Be the Match Registry.

"I cant change the past but I can ensure that in the future nobody else like Marlon has to be waiting for a marrow registrant from somebody whos of their same race," says Ogilvy & Mather Marketing Analytics Associate Director Omari Jinaki.

Omari Jinaki says he has noticed a level of hesitancy to participate within the black community, though.

"That is rooted, clearly, in hundreds of years of history of being misguided and misrepresented and underrepresented by the systems that are supposed to protect us," Jinaki says.

There's also a lack of awareness of the need within the Latino and Asian communities, and lingering misconceptions the donation process.

Many believe it's painful, with significant recovery time.

"The process has changed in the way one donates bone marrow. Seventy-five percent of the time, it's just like a blood donation," says Icla Da Silva Foundation President Airam Da Silva.

Depending on the recipient's need, most can now donate via a peripheral blood stem cell, or PBSC.

The rest is here:
Misconceptions Keep Bone Marrow Registry from Attracting Diverse Donor Pool

Miami (PRWEB) July 01, 2014

Global Stem Cells Group announced the grand opening of Regenestem Asia in Manila, Philippines, adding a new state-of-the-art clinic to the international stem cell medicine company's growing worldwide presence. With clinics in Miami, New York, Los Angeles and Dubai, Regenestem Asia now offers the same comprehensive stem cell treatments and experienced medical staff that have fueled the company's worldwide growth.

The launch of Regenestem Asia is a collaborative effort between Global Stem Cells Group and Eric Yalung, M.D. of the Cosmetic Surgery Institute-Manila, Inc., a prominent plastic surgeon committed to taking stem cell medicine, research and practice in the Philippines to a world-class level. The first Regenestem brand clinic in the Philippines, Regenestem Asia is a 22,000 square foot facility with a focus on offering the most advanced protocols in cosmetic cellular medicine to patients from around the world.

Under Yalung's leadership as Regenestem Medical Director, patients will receive the latest and least-invasive techniques in Stem Cell medicine available. Yalung is joined by a team of talented stem cell specialists to provide world-class patient treatment and follow-up care under the Regenestem brand.

In addition to cosmetic treatments, Regenestem offers stem cell treatments for arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes and multiple sclerosis among many other medical conditions at various facilities worldwide.

As part of its commitment to maintaining the highest standards in service and technology, Regenestem Asia provides an international staff experienced in administering the leading cellular therapies available.

Like all Regenestem facilities, Regenestem Asia is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

For more information, visit the Regenestem website, email bnovas(at)regenestem(dot)com or call 305-224-1858.

About Regenestem:

Regenestem is a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialists-professionals trained in the latest cutting-edge techniques in cellular medicine-Regenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.

See more here:
Global Stem Cells Group Subsidiary Regenestem Announces Grand Opening of State-of-the-Art Regenestem Asia Stem Cell ...

Dr Lox Stem Cell Therapy WFLA News 8
Dr. Lox | http://www.drlox.com | 727-462-5582 (WFLA) When Judy Loar, 68, could not bear to walk any longer due to excruciating pain in both of her knees from degenerative joint disease, she did what...

By: Dr. Lox

Visit link:
Dr Lox Stem Cell Therapy WFLA News 8 - Video

Friday 27 June 2014 22.31

Japanese stem cell scientists have succeeded in slowing the deterioration of mice with motor neurone disease, possibly paving the way for eventual human treatment.

A team of researchers from the Kyoto University and Keio University transplanted specially created cells into mice with amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's, or motor neurone disease.

The progress of the creatures' neurological degeneration was slowed by almost eight percent, according to the paper, which was published Thursday in the scholarly journal Stem Cell Reports.

ALS is a disorder of motor neurones -- nerves that control movement -- leading to the loss of the ability to control muscles and their eventual atrophy.

While it frequently has no effect on cognitive function, it progresses to affect most of the muscles in the body, including those used to eat and breathe.

British theoretical physicist Stephen Hawking has been almost completely paralysed by the condition.

In their study, the Japanese team used human "iPS" -- induced pluripotent stem cells, building-block cells akin to those found in embryos, which have the potential to turn into any cell in the body.

From the iPS cells they created special progenitor cells and transplanted them into the lumbar spinal cord of ALS mice.

Animals that had been implanted lived 7.8% longer than the control group without the procedure, the paper said.

See the rest here:
Scientists slow degeneration in motor neurone mice

PUBLIC RELEASE DATE:

25-Jun-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 25, 2014Mary Ann Liebert, Inc., publishers website and Genetic Engineering & Biotechnology News (GEN) are proud to announce that they will again serve as joint platinum media sponsors of the Genetics Policy Institute 2014 World Stem Cell Summit that will take place at the Marriott River Center, December 4-6, 2014 in San Antonio, Texas.

In a new collaborative effort in 2014, Mary Ann Liebert, Inc. will also organize a World Stem Cell Summit panel, comprised of leading editors from their peer-reviewed journals intersecting the field to predict the most innovative translational research that will impact regenerative medicine in the next five years.

Mary Ann Liebert, Inc. will also publish the 2014 World Stem Cell Report as a special supplement to the peer-reviewed journal Stem Cells and Development. Dr. Graham Parker, Editor-in-Chief of Stem Cells and Development, and Bernard Siegel, Executive Director of Genetics Policy Institute (GPI), will serve as Co-Editors-in-Chief of the Report, joined by Rosario Isasi (McGill University) as Managing Editor. The World Stem Cell Report will be made available to all subscribers of Stem Cells and Development and attendees of the World Stem Cell Summit. It will also be available free online in 106 developing countries, courtesy of the Publisher, to facilitate global stem cell research.

"We are very pleased to expand our collaboration with Mary Ann Liebert, Inc., and GEN," says Bernard Siegel, Founder and Co-chair of the Summit. "The commitment by those prestigious publishers to journalistic integrity and scientific knowledge and education matches our enthusiasm to advance the field of stem cells and regenerative medicine for the betterment of humanity. We look forward to working with Graham Parker and the skilled editorial team at Stem Cells and Development to publish our annual Report. We are especially excited to have the expertise of the Liebert editors engaged on the program at the World Stem Cell Summit."

"The World Stem Cell Summit is unequivocally a paramount meeting that brings together the leaders in the field from academia, industry, and business, thereby ensuring the advancement of collaborative opportunities," says Mary Ann Liebert, publisher & CEO of both Stem Cells and Development and GEN. "Bernie Siegel and GPI also recognize the importance of public advocacy at this most important international conference. Mary Ann Liebert, Inc. is delighted to expand our own collaboration with Bernie Siegel and GPI and to publish the 2014 Report.

GEN Editor-in-Chief John Sterling stated, "The World Stem Cell Summit is the critical global meeting, providing the best opportunity for the GEN community to participate in the world of regenerative medicine. Our platinum media sponsorship allows GEN readers and advertisers to have a front row seat to listen and learn from the top experts on the very dynamic and expertly conceptualized Summit platform."

The Summit program delivers on the "big picture," featuring over 200 prominent scientists, business leaders, regulators, policy-makers, advocates, economic development officers, experts in law and ethics, and visionary gurus who will discuss the latest scientific discoveries, business models, legal and regulatory solutions, and best practices. The Summit is expected to attract attendees from more than 40 nations.

The rest is here:
2014 World Stem Cell Summit presented by GPI, Mary Ann Liebert, Inc, and GEN

Stratford, CT (PRWEB) June 24, 2014

Consumers should be aware of four things before buying skin care which are the ingredients, the formulation and the science to support the claims. The final thing they should notice are the results.

It had been several years since the anti-aging category had skyrocketed. Women are realizing that they can indeed skip the invasive procedures and reverse the signs of premature ageing skin with the help of a few bottles and jars. Theres just one catch, theyre just not bottles and jars; its Innarah. Innarah is the skin care collection that will change the way women feel about their skin.

Innarah is the first ever formulated skin care that works with the skins immune system.

Mr. Manzoor H. Jaffery, CEO Innarah Inc. has formulated a unique technology known as biofermentation. Mr. Jaffery perfected these fermented, anti-aging formulas and signature VenoDefense collection, which replicates the effects of snake venom using a botanical base with cutting edge ingredients such as Elk Antler Velvet, Ormus Gold, Plant Stem Cells and Marine Phytoplankton.

After being dissatisfied with so many skin care products on the market, Mr. Jaffery wanted something that really worked. Jaffery developed a process called Bioferm that is modelled on the ancient alchemic process called Nigredo, whose sole purpose is to transform the life force within matter. This process is actually different from other product formulations where the trick is their blending process. So, in essence, because Innarahs ingredients are fermented, there is no danger of the ingredients going through an oxidation process; plus, the result is a much more powerful cream.

As Jaffery explains, The ingredients are powerful, just like raw food. It helps with the skins own immune system. Many might dismiss this as hogwash, but listen to the science behind this for a bit. Because the skin is the largest organ in the body, and is the first line of defense in the immune system, its imperative to help protect it. This is why people recommend to eat daily fruits and vegetables.

Now, how can a skin care cream help with the immune system? It all has to do with the reticulation of Langerhans Cells, which are white blood cells generated in the bone marrow, Jaffery goes on to say. When they arrive at the epidermis, they develop small legs or dendrites, and automatically generate an immune response to the skin when they come into contact with ingredients they dont recognize. But ingredients that have been through the biofermentation process are readily accepted by these cells, so in essence Innarah acts as a bio catalyst.

Innarah is one of the few companies that offers an Oxygenated Crme that helps the healing of adult acne, cold sores, hyperpigmentation and other skin issues. Using Innarah products also aid the skin by diffusing and removing under eye puffiness and inflammation.

Innarah is for any skin color or gender and is recommended for people between 25-85 years old. Innarah is for that glow from-within associated with youth.

Link:
The Discovery of a Unique Skincare System Which Acts as Food for the Skin and Absorb Immediately Reducing the ...

San Diego is buzzing about biotech this week: The BIO International Convention is in town at the San Diego Convention Center. While the conference has drawn big names like entrepreneur Sir Richard Branson and former Secretary of State Hillary Clinton as its keynote speakers, it's not just the guests who are making headlines.

Companies are announcing new ventures and clinical trials on a wide range of bio-tech topics, including regenerative medicine and stem cells.

A popular method now being used by stem cell researchers is known as "disease in a dish." The process uses a patient's own skin cells and manipulates them into stem cells. The cells are then tested with drug combinations right in the Petri dish to determine if they might assist with a condition or disease. But even though these cells, known as IPS cells, are not controversial embryonic cells, ethical questions about their use remain.

Read more here:
BIO Convention Puts Spotlight On San Diego Stem-Cell Research

PUBLIC RELEASE DATE:

9-Jun-2014

Contact: Lucia Lee NewsMedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine

(New York June 9, 2014) -- A protein may be the key to maintaining the health of aging blood stem cells, according to work by researchers at the Icahn School of Medicine at Mount Sinai recently published online in Stem Cell Reports. Human adults keep stem cell pools on hand in key tissues, including the blood. These stem cells can become replacement cells for those lost to wear and tear. But as the blood stem cells age, their ability to regenerate blood declines, potentially contributing to anemia and the risk of cancers like acute myeloid leukemia and immune deficiency. Whether this age-related decline in stem cell health is at the root of overall aging is unclear.

The new Mount Sinai study reveals how loss of a protein called Sirtuin1 (SIRT1) affects the ability of blood stem cells to regenerate normally, at least in mouse models of human disease. This study has shown that young blood stem cells that lack SIRT1 behave like old ones. With use of advanced mouse models, she and her team found that blood stem cells without adequate SIRT1 resembled aged and defective stem cells, which are thought to be linked to development of malignancies.

"Our data shows that SIRT1 is a protein that is required to maintain the health of blood stem cells and supports the possibility that reduced function of this protein with age may compromise healthy aging," says Saghi Ghaffari, MD, PhD, Associate Professor of Developmental and Regenerative Biology at Mount Sinai's Black Family Stem Cell Institute, Icahn School of Medicine. "Further studies in the laboratory could improve are understanding between aging stem cells and disease."

Next for the team, which includes Pauline Rimmel, PhD, is to investigate whether or not increasing SIRT1 levels in blood stem cells protects them from unhealthy aging or rejuvenates old blood stem cells. The investigators also plan to look at whether SIRT1 therapy could treat diseases already linked to aging, faulty blood stem cells.

They also believe that SIRT1 might be important to maintaining the health of other types of stem cells in the body, which may be linked to overall aging.

The notion that SIRT1 is a powerful regulator of aging has been highly debated, but its connection to the health of blood stem cells "is now clear," says Dr. Ghaffari. "Identifying regulators of stem cell aging is of major significance for public health because of their potential power to promote healthy aging and provide targets to combat diseases of aging," Dr. Ghaffari says.

###

Here is the original post:
Mount Sinai researchers identify protein that keeps blood stem cells healthy as they age

Tampa, FL (PRWEB) June 19, 2014

Located in Tampa, FL, Lung Institute was instrumental in allowing Robert Ware get his life back. Three months ago, Robert decided to take his health into his own hands and move ahead with stem cell treatment. Hundreds of people with lung disease have been treated with the companys innovative use of stem cells from the patients own body.

Stem cell therapy is a viable option for many people with lung disease, said Dr. Burton Feinerman, Medical Director of the Lung Institute. Our patients are breathing easier, walking further, and depending less on supplemental oxygen.

For Robert, 71, chronic obstructive pulmonary disease (COPD) was taking over his life. Over the past decade, this progressive lung disease diminished his quality of life and forced him away from the activities he used to love. Robert was unable to be outdoors, attend live music shows in the town squares and work on his yard and landscaping. A few months ago, Robert had a health scare that he thought was a heart attack. He was actually experiencing lung spasms and not receiving enough oxygen, often referred to as a COPD exacerbation.

COPD is not only the third leading cause of death in the United States, but is responsible for severely limiting sufferers quality of life. People with COPD often cant even walk to their mailbox without debilitating shortness of breath. For people without COPD, it is akin to breathing through a small straw while carrying out normal activities.

In Roberts case, his exacerbation caused him to look for alternatives to the traditional medications he had been taking. Robert and his wife decided stem cell therapy at the Lung Institute was the best option for him. Robert received autologous stem cell therapy, meaning stem cells from his own body were used to help cue natural healing processes for damaged lung tissue. After the minimally invasive, outpatient procedure, Robert returned home and was able to regain a substantial amount of his quality of life.

Before treatment, I was pretty much on oxygen all the time, said Robert. I couldnt do much without my oxygen. Today, Im doing just about anything I want to do.

Now, Robert no longer needs to pay someone to take care of his lawn. Robert is able to be outdoors, mow the grass, work around the house and go out with friends.

People are just amazed how well Im doing. Im probably 75% to what I was originally, 10 years ago, added Robert. I started getting better fast and my friends couldnt believe it. They were shocked. It was kind of funfeeling good, rather than being sick.

About Lung Institute At Lung Institute (LI), we are changing the lives of hundreds of people across the nation through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, visit our website at LungInstitute.com, like us on Facebook, follow us on Twitter or call us today at 1-855-469-5864.

Read the original here:
Lung Institute Instrumental in Allowing Robert Ware to Get His Life Back

June 17, 2014

Image Caption: ImStem Biotechnologys Xiaofang Wang, seated, and Ren-He Xu. Credit: Tina Encarnacion/UConn

University of Connecticut

Scientists in the University of Connecticuts Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using human embryonic stem cells, offering a promising new therapy for more than 2.3 million people suffering from the debilitating disease.

The researchers demonstrated that the embryonic stem cell therapy significantly reduced MS disease severity in animal models, and offered better treatment results than stem cells derived from human adult bone marrow.

The study was led by ImStem Biotechnology Inc. of Farmington, Conn., in conjunction with UConn Health Professor Joel Pachter, Assistant Professor Stephen Crocker, and Advanced Cell Technology (ACT) Inc. of Massachusetts. ImStem was founded in 2012 by UConn doctors Xiaofang Wang and Ren-He Xu, along with Yale University doctor Xinghua Pan and investor Michael Men.

The cutting-edge work by ImStem, our first spinoff company, demonstrates the success of Connecticuts Stem Cell and Regenerative Medicine funding program in moving stem cells from bench to bedside, says Professor Marc Lalande, director of the UConns Stem Cell Institute.

The research was supported by a $1.13 million group grant from the state of Connecticuts Stem Cell Research Program that was awarded to ImStem and Professor Pachters lab.

Connecticuts investment in stem cells, especially human embryonic stem cells, continues to position our state as a leader in biomedical research, says Gov. Dannel P. Malloy. This new study moves us one step closer to a stem cell-based clinical product that could improve peoples lives.

The researchers compared eight lines of adult bone marrow stem cells to four lines of human embryonic stem cells. All of the bone marrow-related stem cells expressed high levels of a protein molecule called a cytokine that stimulates autoimmunity and can worsen the disease. All of the human embryonic stem cell-related lines expressed little of the inflammatory cytokine.

Link:
Embryonic Stem Cells Offer Promising Treatment For Multiple Sclerosis